Lv31
371 积分 2023-08-23 加入
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
7小时前
已完结
Foxiangsan Modulates Dopaminergic and Motilin Pathways to Improve Gastrointestinal Motility in Diabetic Gastroparesis
30天前
已完结
Surufatinib combined with sintilimab and IBI310 for the treatment of high‐grade advanced‐neuroendocrine neoplasms: A single arm, open‐label, single‐center, phase II study
1个月前
已完结
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
1个月前
已完结
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases
1个月前
已完结
Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study
1个月前
已完结
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
1个月前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
1个月前
已完结
Outcomes of icotinib combined with concurrent chemoradiotherapy in locally advanced cervical cancer
2个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
